Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

President’s address: Treatment of tamoxifen-refractory breast cancer — approach by animal models

This is a preview of subscription content, log in to check access.

References

  1. 1)

    Nomura Y, Tashiro H, Shinozuka K,et al: Changes of steroid hormone receptor content by chemotherapy and/or endocrine therapy in advanced breast cancer.Cancer 55: 546–551, 1985.

  2. 2)

    Ottaviano YL, Issa JP, Parl FF,et al: Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells.Cancer Res 54: 2552–2555, 1994.

  3. 3)

    Watts CKW, Handel ML, King RJB,et al: Oestrogen receptor gene structure and function in breast cancer.J Steroid Biochem Mol Biol 41: 529–536, 1992.

  4. 4)

    Karni PS, Kulkarni S, Liu X-P,et al: Estrogen receptor mutations in tamoxifen-resistant breast cancer.Cancer Res 54: 349–353, 1994.

  5. 5)

    Wolf DM, Jordan VC: The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain.Breast Cancer Res Treat 31: 129–138, 1994.

  6. 6)

    Levenson AS, Catherino WH, Jordan VC: Estrogenic activity is increased for an antiestogen by natural mutation of the estogen receptor.J Steroid Biochem Mol Biol 60: 261–268, 1997.

  7. 7)

    Levenson AS, Jordan VC: The key to the antiestrogenic mechanism of raloxifen is amino acid 351 (Aspartate) in the estrogen receptor.Cancer Res 58: 1872–1875, 1998.

  8. 8)

    Speirs V, Malone C, Walton DS,et al: Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients.Cancer Res 59: 5421–5424, 1999.

  9. 9)

    Paech K, Webb P, Kuiper GGJM,et al: Differential ligand activation of estrogen receptors ER α and ER β at AP1 sites.Science 277: 1508–1510, 1997.

  10. 10)

    Fujimoto N, Katzenellenbogen BS: Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: Antiestrogen selectivity and promoter dependence.Mol Endocrinol 8: 296–304, 1994.

  11. 11)

    Webb P, Lopez GN, Uht RM,et al: Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens.Mol Endocrinol 9: 443–446, 1995.

  12. 12)

    Jordan VC: Designer estrogens.Scientific American 279: 60–67, 1998.

  13. 13)

    Knabbe C, Kopp A, Hilgers W,et al: Regulation and role of TGF beta production in breast cancer.Ann NY Acad Sci 784: 263–276, 1996.

  14. 14)

    MacCallun J, Keen JC, Bartlett JMS,et al: Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy.Br J Cancer 74: 474–478, 1996.

  15. 15)

    Herman ME, Katzenellenbogen BS: Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen.J Steroid Biochem Mol Biol 59: 121–134, 1996.

  16. 16)

    Arteaga CL, Koli KM, Dugger TC,et al: Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta.J Natl Cancer Inst 91: 46–53, 1999.

  17. 17)

    Kopp A, Jonat W, Schmahl M,et al: Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen.Cancer Res 55: 4512–4515, 1995.

  18. 18)

    Gasparini G, Toi M, Miceli R,et al: Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.Cancer J Sci Am 5: 101–111, 1999.

  19. 19)

    Ruohola JK, Valve EM, Karkkainen MJ,et al: Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells.Mol Cell Endocrinol 149: 29–40, 1999.

  20. 20)

    DiGiovanna MP: Clinical significance of HER-2/neu over-expression: Part 1. In: Rosenberg SA, ed. Principles and Practice of Oncology Updates (Vol 13, No 9). PA: Lippincott Williams & Wilkins, Philadelphia, 1999.

  21. 21)

    Tour AD, Liu S, Edgerton S,et al: Activation (Tyrosine Phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer.J Clin Oncol 18: 3230–3239, 2000.

  22. 22)

    Johnston SRD, Haynes BP, Sacks NPM,et al: Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration.Lancet 342: 1521–1522, 1993.

  23. 23)

    Osborne CK, Coronado EB, Wiebe VJ,et al: Acquired tamoxifen resistance: Correlation with reduced tumor levels of tamoxifen and isomerization of trans-4-hydrox-ytamoxifen.J Natl Cancer Inst 83: 1477–1482, 1991.

  24. 24)

    Wieve VJ, Osborne CK, McGuire WL,et al: Identification of estrogenic tamoxifen metabolite (s) in tamoxifen-resistant human breast tumors.J Clin Oncol 10: 990–994, 1992.

  25. 25)

    Wolf DM, Langan-Fahey SM, Parker CJ,et al: Investigation on the mechanism of tamoxifen-stimulated breast tumor growth using nonisomerizable analogs of tamoxifen and metabolites.J Natl Cancer Inst 85: 805–812, 1993.

  26. 26)

    Jordan VC, Fritz NF, Langan-Fahey S,et al: Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent.J Natl Cancer Inst 83: 1488–1491, 1991.

  27. 27)

    Lum SS, Woltering EA, Fletcher WS,et al: Changes in serum estrogen levels in women during tamoxifen therapy.Am J Surg 173: 399–402, 1997.

  28. 28)

    Harada N: Aromatase and intracrinology of estrogen in hormone- dependent tumors.Oncology 57 (Suppl 2): 7–16, 1999.

  29. 29)

    Iino Y, Ogawa T, Yoshida M,et al: Effects of OK-432 (Picibanil) on estrogen receptor levels and tamoxifen treatment in 7,12-dimethylbenz [a] anthracene-induced rat mammary cancers.Oncology 47: 185–190, 1990.

  30. 30)

    Iino Y, Yoshida M, Tago T,et al: Effects of sequential and combined immuno-endocrine therapies using OK-432 (picibanil) and tamoxifen on the growth of 7,12-dimethylbenz [a] anthracene-induced rat mammary carcinoma.Jpn J Clin Oncol 21: 35–38, 1991.

  31. 31)

    Iino Y, Wolf DM, Langan-Fahey SM,et al: Reversible control of estradiol-stimulated growth of MCF-7 tumors by tamoxifen in the athymic mouse.Br J Cancer 64:1019–1024.

  32. 32)

    Takei H, Lee ES, Cisneros A,et al: Effects of angiogenesis inhibitor TNP-470 on tamoxifen-stimulated MCF-7 breast tumors in nude mice.Cancer Lett 155: 129–135, 2000.

Download references

Author information

Correspondence to Yuichi Iino.

Additional information

Reprint requests to Yuichi lino, Department of Emergency and Critical Care Medicine, Gunma University Faculty of Medicine, 3-39-15 Showamachi, Maebashi, Gunma 371–8511, Japan.

About this article

Cite this article

Iino, Y. President’s address: Treatment of tamoxifen-refractory breast cancer — approach by animal models. Breast Cancer 8, 262–264 (2001). https://doi.org/10.1007/BF02967522

Download citation

Key words

  • Hormone-dependent breast cancer
  • TAM refractoriness
  • DMBA-induced rat mammary tumor
  • MCF-7 tumor
  • Angiogenesis inhibitor